Selective alpha 7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3 beta and decreases tau phosphorylation in vivo

• Published in: Brain research 2009-04, Vol.1265, p.65-74
• Main Authors: Bitner, R S, Nikkel, AL, Markosyan, S, Otte, S, Puttfarcken, P, Gopalakrishnan, M
• Format: Article
• Language: English
• ISSN: 0006-8993
• DOI: 10.1016/j.brainres.2009.01.069

The alpha 7 nicotinic acetylcholine receptor (nAChR) plays an important role in cognitive processes and has generated recent interest as a potential drug target for treating neurodegenerative disorders such as Alzheimer's disease (AD). The property of Ca super(2) super(+) permeation associated with alpha 7 nAChR agonism may lead to Ca super(2) super(+)-dependent intracellular signaling that contribute to the procognitive and neuroprotective effects that have been described with this pharmacology. In this study, we investigated whether alpha 7 nAChR agonism leads to increased phosphorylation of the inhibitory regulating amino acid residue Ser-9 on GSK3 beta , a major kinase responsible for tau hyperphosphorylation in AD neuropathology. Immunohistochemical analysis revealed that the selective alpha 7 agonist A-582941 increased S super(9)-GSK3 beta phosphorylation in mouse cingulate cortex and hippocampus that was not observed in alpha 7 nAChR knock-out mice. A-582941 steady state exposure through continuous (2 wk) infusion also increased S super(9)-GSK3 beta phosphorylation in the hippocampus of Tg2576 (APP), as well as wild-type mice. Moreover, A-582941 continuous infusion decreased phosphorylation of tau in hippocampal CA3 Mossy fibers and spinal motoneurons in a hypothermia-induced tau hyperphosphorylation mouse model and AD double transgenic APP/tau mouse line, respectively. These studies demonstrate that inactivation of GSK3 beta may be associated with alpha 7 nAChR-induced signaling leading to attenuated tau hyperphosphorylation, raising the intriguing possibility that alpha 7 nAChR agonism may have disease modifying benefit in the treatment of tauopathies, in particular AD.